Awards
Host-Directed Therapeutics for the Prevention of Progression to ARDS
Member Organization: AstraZeneca Pharmaceuticals LP
Award Date: 09/29/2026
Award Amount: $48,384,562
Project Duration: 29 Months
Bundibugyo Virus Outbreak Response Vaccines (BundiVx)
Awards Made: 1
Total Amount Awarded: $36,382,096
Threat Agnostic Diagnostics
Awards Made: 1
Total Amount Awarded: $10,196,058
Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory Services
Member Organization: Duke University
Award Date:12/23/2025
Award Amount: $1,492,307
Project Duration: 45 Months
COVID-19 Small Molecule Therapeutics for PrEP
Member Organization: Shionogi
Award Date: 01/15/2025
Award Amount: $375,529,647
Project Duration: 84 Months
NextGen Vaccines: Immune Assays
Member Organization: Fred Hutchinson Cancer Center
Award Date: 12/23/2024
Award Amount: $23,826,661
Project Duration: 72 months
| Solicitation # | Solicitation Topic | Award Date | RRPV Member Awarded | Base Award | Focus Area |
|---|---|---|---|---|---|
| RPP-25-06-DxR2 | 10/26/2026 | Uh-Oh Labs Inc. dba Scout | $6,760,145 | Medical Technology | |
| RPP-25-06-DxR2 | Biothreat Diagnostic Rapid Response | 10/9/2026 | InBios International, Inc | $7,477,676 | Medical Technology |
| RPP-25-06-DxR2 | Biothreat Diagnostic Rapid Response | 10/05/2026 | Chembio Diagnostic Systems, Inc. | $5,697,531 | Medical Technology |
| RPP-26-09-AgDx | Threat Agnostic Diagnostics | 09/29/2026 | Signature Science LLC | $10,196,058 | Medical Technology |
| RPP-26-12-ARDS | Host-Directed Therapeutics for the Prevention of Progression to ARDS | 9/29/2026 | AstraZeneca Pharmaceuticals LP | $48,343,562 | Vaccines and Therapeutics |
| RPP-26-13-BundiVx | 9/29/2026 | International Aids Vaccine Initiative, Inc. | $36,382.096 | Vaccines and Therapeutics | |
| RPP-24-06-DxR2 | Biothreat Diagnostic Rapid Response | 9/10/2026 | BioFire Defense, LLC | $4,717,078 | Medical Technology |
| RPP-25-06-DxR2 | Biothreat Diagnostics Rapid Response | 07/14/2026 | Sapphiros | $12,378,391 | Medical Technology |
| RRPV 24-07-CentralIEIDLab | Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory Services | 12/23/2025 | Duke University | $1,492,307 | Vaccines and Therapeutics |
| RPP-24-06-DxR2 | Biothreat Diagnostics Rapid Response | 09/30/2025 | True Diagnostics, Inc. | $10,999,987 | Medical Technology |
| RPP-24-06-DxR2 | Biothreat Diagnostic Rapid Response | 04/03/2025 | Aptitude Medical Systems Inc. | $9,063,082 | Medical Technology |
| RPP-24-03-SmMol | 01/15/2025 | Shionogi | $375,529,647 | Vaccines and Therapeutics | |
| RPP-24-04-NGVxAssays | NextGen Vaccines: Immune Assays | 12/23/2024 | Fred Hutchinson Cancer Center | $23,826,661 | Vaccines and Therapeutics |
| RPP-24-06-DxR2 | Biothreat Diagnostic Rapid Response | 11/26/2024 | OraSure Technologies, Inc. | $7,553,929 | Medical Technology |
| RPP-24-06-DxR2 | Biothreat Diagnostic Rapid Response | 09/30/2024 | InBios International, Inc | $16,511,354 | Medical Technology |
| RPP-24-04-NGVxStats | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis: Module 1 | 07/22/2024 | Fred Hutchinson Cancer Center | $16,500,000 | Vaccines and Therapeutics |
| RPP-24-04-NGVxStats | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis: Module 2 | 07/22/2024 | Fred Hutchinson Cancer Center | $500,000 | Vaccines and Therapeutics |
| RPP-24-02-Retail | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 07/19/2024 | Walgreen Co. | $25,000,000 | Vaccines and Therapeutics |
| RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 06/28/2024 | ModernaTX, Inc. | $176,000,000 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/13/2024 | Vaxart, Inc. | $452,884,477 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/12/2024 | GeoVax, Inc. | $24,321,841 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/04/2024 | CyanVac, LLC | $40,167,897 | Vaccines and Therapeutics |
| RPP-24-04-NGVx | Next Gen Vaccinations: Phase 2b Clinical Trial Execution | 06/03/2024 | CastleVax, Inc. | $33,793,676 | Vaccines and Therapeutics |
| RPP-24-02-HomeFocus | Enabling Technology – Decentralized Clinical Trial – Home Focus | 05/14/2024 | Allucent | $25,514,420 | Vaccines and Therapeutics |